- Report
- January 2021
- 145 Pages
China, Global
From €3000EUR$3,346USD£2,673GBP
- Report
- September 2022
- 60 Pages
Global
From €1921EUR$2,000USD£1,654GBP
- Drug Pipelines
- March 2021
Global
From €1921EUR$2,000USD£1,654GBP
- Report
- April 2023
- 263 Pages
Global
From €3429EUR$3,570USD£2,952GBP
- Report
- February 2023
- 300 Pages
Global
From €3429EUR$3,570USD£2,952GBP
- Report
- April 2023
- 147 Pages
Global
From €5762EUR$5,999USD£4,961GBP
Rituximab is a monoclonal antibody used to treat a variety of immune disorders, including rheumatoid arthritis, systemic lupus erythematosus, and non-Hodgkin's lymphoma. It works by targeting and destroying B-cells, which are a type of white blood cell involved in the body's immune response. Rituximab is administered intravenously and is often used in combination with other drugs.
Rituximab is a relatively new drug, having been approved by the US Food and Drug Administration in 1997. Since then, it has become a popular treatment for immune disorders, due to its effectiveness and relatively low side effects. It is also used off-label to treat a variety of other conditions, such as multiple sclerosis and vasculitis.
The market for rituximab is highly competitive, with several major pharmaceutical companies producing the drug. These include Roche, Merck, Pfizer, and Biogen. Additionally, there are several generic versions of the drug available, produced by companies such as Sandoz and Teva Pharmaceuticals. Show Less Read more
